Cargando…
New Treatment Options in Advanced Stage Follicular Lymphoma
Follicular lymphoma is one of the most common non-Hodgkin's lymphomas with an expected survival of more than 20 years for the majority of patients. This impressive outcome has been achieved with the introduction of immunochemotherapy, as first line treatment with remissions lasting over 8 years...
Autores principales: | Hübel, Kai, Salles, Gilles, Marcus, Robert, Zinzani, Pier Luigi, Dreyling, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745966/ https://www.ncbi.nlm.nih.gov/pubmed/31723794 http://dx.doi.org/10.1097/HS9.0000000000000156 |
Ejemplares similares
-
Controversies in the Treatment of Follicular Lymphoma
por: Hübel, Kai, et al.
Publicado: (2020) -
The role of tazemetostat in relapsed/refractory follicular lymphoma
por: von Keudell, Gottfried, et al.
Publicado: (2021) -
Radiotherapy for early and advanced stages Follicular Lymphoma
por: Mauro, Geovanne Pedro, et al.
Publicado: (2021) -
Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis
por: Ferreri, Andrés J. M., et al.
Publicado: (2023) -
EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma
por: Ladetto, Marco, et al.
Publicado: (2021)